152 related articles for article (PubMed ID: 16505497)
1. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes.
Basu A; Jensen MD; McCann F; Mukhopadhyay D; Joyner MJ; Rizza RA
Diabetes Care; 2006 Mar; 29(3):510-4. PubMed ID: 16505497
[TBL] [Abstract][Full Text] [Related]
2. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes.
Basu A; Jensen MD; McCann F; Nandy D; Mukhopadhyay D; McConnell JP; Rizza RA
Endocr Pract; 2007; 13(2):147-52. PubMed ID: 17490928
[TBL] [Abstract][Full Text] [Related]
3. Effects of intensive insulin therapy alone and in combination with pioglitazone on body weight, composition, distribution and liver fat content in patients with type 2 diabetes.
Shah PK; Mudaliar S; Chang AR; Aroda V; Andre M; Burke P; Henry RR
Diabetes Obes Metab; 2011 Jun; 13(6):505-10. PubMed ID: 21272186
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.
Henriksen K; Byrjalsen I; Qvist P; Beck-Nielsen H; Hansen G; Riis BJ; Perrild H; Svendsen OL; Gram J; Karsdal MA; Christiansen C;
Diabetes Metab Res Rev; 2011 May; 27(4):392-401. PubMed ID: 21328517
[TBL] [Abstract][Full Text] [Related]
5. Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
Smith SR; De Jonge L; Volaufova J; Li Y; Xie H; Bray GA
Metabolism; 2005 Jan; 54(1):24-32. PubMed ID: 15562376
[TBL] [Abstract][Full Text] [Related]
6. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.
Tan M; Johns D; González Gálvez G; Antúnez O; Fabián G; Flores-Lozano F; Zúñiga Guajardo S; Garza E; Morales H; Konkoy C; Herz M;
Clin Ther; 2004 May; 26(5):680-93. PubMed ID: 15220012
[TBL] [Abstract][Full Text] [Related]
7. Reduction in hematocrit and hemoglobin following pioglitazone treatment is not hemodilutional in Type II diabetes mellitus.
Berria R; Glass L; Mahankali A; Miyazaki Y; Monroy A; De Filippis E; Cusi K; Cersosimo E; Defronzo RA; Gastaldelli A
Clin Pharmacol Ther; 2007 Sep; 82(3):275-81. PubMed ID: 17361126
[TBL] [Abstract][Full Text] [Related]
8. Meal fat storage in subcutaneous adipose tissue: comparison of pioglitazone and glipizide treatment of type 2 diabetes.
Basu A; Basu R; Pattan V; Rizza RA; Jensen MD
Obesity (Silver Spring); 2010 Oct; 18(10):2058-60. PubMed ID: 20539300
[TBL] [Abstract][Full Text] [Related]
9. Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects.
Cefalu WT; Schneider DJ; Carlson HE; Migdal P; Gan Lim L; Izon MP; Kapoor A; Bell-Farrow A; Terry JG; Sobel BE
Diabetes Care; 2002 Dec; 25(12):2123-8. PubMed ID: 12453948
[TBL] [Abstract][Full Text] [Related]
10. Combination peroxisome proliferator-activated receptor gamma and alpha agonist treatment in Type 2 diabetes prevents the beneficial pioglitazone effect on liver fat content.
Balasubramanian R; Gerrard J; Dalla Man C; Firbank MJ; Lane A; English PT; Cobelli C; Taylor R
Diabet Med; 2010 Feb; 27(2):150-6. PubMed ID: 20546257
[TBL] [Abstract][Full Text] [Related]
11. The effect of pioglitazone and resistance training on body composition in older men and women undergoing hypocaloric weight loss.
Shea MK; Nicklas BJ; Marsh AP; Houston DK; Miller GD; Isom S; Miller ME; Carr JJ; Lyles MF; Harris TB; Kritchevsky SB
Obesity (Silver Spring); 2011 Aug; 19(8):1636-46. PubMed ID: 21233810
[TBL] [Abstract][Full Text] [Related]
12. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
Miyazaki Y; Mahankali A; Matsuda M; Mahankali S; Hardies J; Cusi K; Mandarino LJ; DeFronzo RA
J Clin Endocrinol Metab; 2002 Jun; 87(6):2784-91. PubMed ID: 12050251
[TBL] [Abstract][Full Text] [Related]
13. [Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin].
Nauck M; del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S6-15. PubMed ID: 23529570
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.
Ito D; Shimizu S; Inoue K; Saito D; Yanagisawa M; Inukai K; Akiyama Y; Morimoto Y; Noda M; Shimada A
Diabetes Care; 2017 Oct; 40(10):1364-1372. PubMed ID: 28751548
[TBL] [Abstract][Full Text] [Related]
15. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone.
Kushner RF; Sujak M
Obesity (Silver Spring); 2009 May; 17(5):1017-22. PubMed ID: 19180065
[TBL] [Abstract][Full Text] [Related]
16. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
[TBL] [Abstract][Full Text] [Related]
17. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
[TBL] [Abstract][Full Text] [Related]
18. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.
Fernandez M; Triplitt C; Wajcberg E; Sriwijilkamol AA; Musi N; Cusi K; DeFronzo R; Cersosimo E
Diabetes Care; 2008 Jan; 31(1):121-7. PubMed ID: 17909084
[TBL] [Abstract][Full Text] [Related]
19. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
20. Effects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitus.
Kodama N; Tahara N; Tahara A; Honda A; Nitta Y; Mizoguchi M; Kaida H; Ishibashi M; Abe T; Ikeda H; Narula J; Fukumoto Y; Yamagishi S; Imaizumi T
J Clin Endocrinol Metab; 2013 Nov; 98(11):4438-45. PubMed ID: 24030946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
